The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis

Am J Hematol. 2016 Jul;91(7):E320-1. doi: 10.1002/ajh.24378. Epub 2016 Apr 24.

Bing Li^{1

2}, Zefeng Xu^{1

2}, Yan Li¹, Robert Peter Gale³, Zhen Song⁴, Xiaofei Ai⁵, Tiejun Qin¹, Yue Zhang^{1

2}, Peihong Zhang⁶, Gang Huang⁷, Zhijian Xiao^{1

2}

¹ MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
² State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
³ Division of Experimental Medicine, Department of Medicine, Imperial College London, Haematology Research Center, London, United Kingdom.
⁴ Medical Service Division, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁵ Molecular Diagnostic Laboratory, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁶ Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁷ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

No abstract available

Publication types